- 全部删除
您的购物车当前为空
Icotinib Hydrochloride (BPI-2009H) 是一种口服的基于喹唑啉的表皮生长因子受体 (EGFR) 抑制剂,IC50值为5 nM,具有潜在的抗肿瘤活性。

Icotinib Hydrochloride (BPI-2009H) 是一种口服的基于喹唑啉的表皮生长因子受体 (EGFR) 抑制剂,IC50值为5 nM,具有潜在的抗肿瘤活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 459 | In stock | |
| 5 mg | ¥ 826 | In stock | |
| 10 mg | ¥ 1,150 | In stock | |
| 25 mg | ¥ 1,960 | In stock | |
| 50 mg | ¥ 3,250 | In stock | |
| 100 mg | ¥ 4,650 | In stock | |
| 200 mg | ¥ 6,480 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 777 | In stock |
Icotinib Hydrochloride 相关产品
| 产品描述 | Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types. |
| 靶点活性 | EGFR:5 nM |
| 别名 | 盐酸埃克替尼, 埃克替尼盐酸盐, BPI-2009H |
| 分子量 | 427.88 |
| 分子式 | C22H22ClN3O4 |
| CAS No. | 1204313-51-8 |
| Smiles | Cl.C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| 溶解度信息 | DMSO: 12 mg/mL (28.05 mM), Sonication is recommended. | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
评论内容